AMRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Amneal Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2024 was 0.00.
The historical rank and industry rank for Amneal Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Amneal Pharmaceuticals is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Amneal Pharmaceuticals (NAS:AMRX) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Amneal Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Tushar Bhikhubhai Patel | 10 percent owner | C/O TARSADIA INVESTMENTS, 520 NEWPORT CENTER DRIVE, 21ST FLOOR, NEWPORT BEACH CA 92660 |
Andrew S Boyer | officer: Exec VP, Comm Optns | C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960 |
Tasos Konidaris | officer: SVP and CFO | 103 JFK PARKWAY, SHORT HILLS NJ 07078 |
Gautam Patel | director | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807 |
Deborah M. Autor | director | C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008 |
John Kiely | director | C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286 |
Jason B. Daly | officer: SVP, Chief Legal Officer | 400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807 |
Nikita Shah | officer: SVP, Chief HR Officer | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807 |
Tpg Gp A, Llc | 10 percent owner | 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102 |
Gustavo Pesquin | officer: See Remarks | 4 PARK LANE, MADISON NJ 07940 |
Jon Winkelried | 10 percent owner | C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004 |
Chirag K. Patel | director | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Chintu Patel | director | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807 |
Joseph Todisco | officer: SVP, Specialty Commercial | 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Jeffrey P. George | director | C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
From GuruFocus
By Business Wire • 02-28-2025
By GuruFocus News • 10-09-2024
By GuruFocus News • 01-29-2025
By GuruFocus News • 02-20-2025
By GuruFocus News • 02-06-2025
By GuruFocus News • 01-23-2025
By Business Wire • 01-23-2025
By GuruFocus News • 02-27-2025
By GuruFocus News • 11-07-2024
By GuruFocus News • 03-01-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.